Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib in Indolent Systemic Mastocytosis (Non-D816V)
NCT00831974Phase 2Completed
- Sponsor
- AB Science
- Start
- Oct 2004
- Primary completion
- Feb 2007
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of masitinib in Indolent Systemic Mastocytosis (ISM) (2 arms), sponsored by AB Science. Primary endpoints: Pruritus Score at 12 weeks, Number of flush per day at 12 weeks and 4 more. Started Oct 2004; status: completed.
02
Drugs
masitinib
03
Conditions
Indolent Systemic Mastocytosis (ISM)
Beyond the preview
Go deeper on NCT00831974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00831974.